releases: https://moolenaar.house.gov/media-center/press-releases/moolenaar-peters-stabenow-dingell-urge-fda-take-action-bone-graft
Data license: MIT · Data source: dwillis/congress-press
This data as json
| url | title | date | year | month | party | chamber | state | member_name | bioguide_id | domain | scraper | source | date_source | text | has_text | collected_at | updated_at |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| https://moolenaar.house.gov/media-center/press-releases/moolenaar-peters-stabenow-dingell-urge-fda-take-action-bone-graft | Moolenaar, Peters, Stabenow, Dingell Urge FDA to Take Action on Bone Graft Infections | 2023-08-29 | 2023 | 2023-08 | Republican | House | MI | John R. Moolenaar | M001194 | moolenaar.house.gov | moolenaar | https://moolenaar.house.gov/media-center/press-releases | scraper | Today, Congressman John Moolenaar, U.S. Senators Gary Peters and Debbie Stabenow, and Congresswoman Debbie Dingell called for Food and Drug Administration (FDA) Commissioner Robert Califf to do more to stop the threat of bone graft infections across the U.S. In a letter, the four lawmakers call for the FDA "to issue guidance or regulations based on sound science to protect patients and increase accountability for human tissue transplant products." The call for action comes after the late Shandra Eisenga of Marion passed away from complications from tuberculosis (TB), which she contracted through a bone graft from an infected donor. The infected tissue used in Eisenga's procedure was supplied by Maryland-based Azyio Biologics and 36 patients in seven states have received tissue from the same infected donor. In 2021, Azyio had a similar outbreak, which caused the death of eight patients. "The tragic loss of Shandra Eisenga must be a call to action for Commissioner Califf and the FDA so that no family goes through something like this again. It is clear that the precautions taken after the 2021 TB outbreak have not been enough and that the FDA must do more to protect patients. Commissioner Califf should act urgently to prevent more outbreaks like this one from happening in the future," said Moolenaar. The lawmakers' letter to Commissioner Califf can be found below: Dr. Robert Califf Commissioner U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 Dear Commissioner Califf, We write to express our concerns with the recent outbreak of Tuberculosis (TB) in bone graft material that has led to serious health complications and deaths in our state and around the country. In July 2023, a physician with Michigan Medicine contacted us regarding a TB infection transmitted from a ViBone Allograft to his patient. This patient experienced severe health complications after being one of 36 patients who received infected bone matrix materials that were implanted in patients across the country. Regrettably, on August 10, 2023, the patient passed away due to the TB infection. No patient should suffer such devastating health outcomes from a transplant product. This is not the first TB contamination incident with the company, Azyio Biologics, located in Silver Spring, Maryland. In 2021, a similar outbreak occurred where TB was transmitted via bone graft. The contamination of the infected donor product was placed in up to 100 patients and eight patients lost their lives. Our patients should rely on the integrity of their products, as they are used to improve their health and wellbeing. We have long supported investments into medical research that have produced life changing therapies, products, and pharmaceuticals for patients across the country. While Azyio took proactive testing precautions after the 2021 incident, these precautions were not sufficient to prevent an outbreak two years later. Under the Public Health Service Act, the FDA has authority to determine the parameters of tested communicable diseases, which already includes Hepatitis, Syphilis, and Human Immunodeficiency Virus (HIV). As TB incidence is lower compared to the aforementioned diseases, the prevalence and devastating impacts of these outbreaks calls for prompt action from the FDA. The American Association of Tissue Banks (AATB) is the top accreditor of bone and tissue transplant banks. On August 7, 2023, AATB released Bulletin 23-6, “Requirements and Recommendations for Reducing Risk of Mycobacterium tuberculosis Transmission.” The bulletin outlines donor ineligibility criteria including TB exposure, infection, travel history, and age. We urge the FDA to consider these recommendations and promptly issue guidance or regulations based on sound science to protect patients and increase accountability for human tissue transplant products. | 1 | 2026-03-30T01:40:41Z | 2026-04-08T00:30:18Z |